Financial Performance - The company's operating revenue for Q1 2025 was ¥1,661,846,010.13, a decrease of 19.81% compared to ¥2,072,478,429.77 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥69,258,725.43, representing a decline of 406.40% from a profit of ¥22,603,808.03 in the previous year[4] - The basic earnings per share decreased to -¥0.11, down 375.00% from ¥0.04 in the same period last year[4] - Net profit for Q1 2025 was a loss of ¥67,863,002.26, compared to a profit of ¥47,521,987.16 in Q1 2024[17] - The total equity attributable to shareholders was ¥4,285,970,376.96 in Q1 2025, down from ¥4,354,582,007.41 in Q1 2024[14] - The company's total equity decreased to CNY 2,798,647,234.17 from CNY 2,803,495,366.03, a decline of approximately 0.2%[25] - The total comprehensive income for the period was -4,976,211.79 RMB, compared to -5,573,183.84 RMB in the prior year[26] Cash Flow - The cash flow from operating activities showed a significant improvement, with a net cash flow of ¥116,669,541.90, compared to a negative cash flow of -¥40,845,966.27 in the previous year, marking a 385.63% increase[4] - Cash inflow from operating activities was ¥2,103,042,784.86 in Q1 2025, compared to ¥2,219,850,447.83 in Q1 2024, reflecting a decrease of 5.2%[19] - The net cash flow from operating activities was -25,319,918.73 RMB, compared to -192,986,266.99 RMB in the same period last year, showing a significant reduction in cash outflow[30] - The company's cash and cash equivalents decreased to ¥945,817,244.30 from ¥1,206,525,197.67, representing a decline of about 21.56%[12] - The company's cash and cash equivalents at the end of the period were CNY 682,194,527.34, down from CNY 611,884,719.64, showing a net decrease of CNY 206,870,757.77[20] - Cash inflow from financing activities was 874,205,838.66 RMB, while cash outflow was 993,315,410.14 RMB, leading to a net cash flow of -119,109,571.48 RMB from financing[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,039,401,555.19, a decrease of 1.86% from ¥14,305,542,661.54 at the end of the previous year[5] - The total current assets decreased to CNY 3,350,867,336.73 from CNY 3,655,433,459.03, reflecting a decline of approximately 8.3%[23] - The total liabilities decreased to ¥9,174,000,000.00 from ¥9,500,000,000.00, reflecting a reduction of approximately 3.43%[12] - The company's total liabilities decreased to CNY 5,736,728,905.55 from CNY 6,041,694,331.77, indicating a reduction of about 5.0%[24] - The company's long-term borrowings increased to ¥787,127,257.71 in Q1 2025 from ¥661,578,715.54 in Q1 2024, representing a growth of 18.9%[14] - The company's long-term equity investments rose to ¥1,465,506,304.57 from ¥1,442,616,370.31, an increase of about 1.59%[12] Operational Challenges - The gross profit margin decreased by approximately 6% compared to the same period last year, leading to a total gross profit reduction of ¥210 million[7] - The company faced challenges due to price reductions in certain regions, impacting revenue and profit margins significantly[7] - The company is focusing on controlling costs and expenses to adapt to market changes despite the revenue decline[7] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 75,979[9] Other Financial Metrics - The weighted average return on equity was -1.60%, a decrease of 2.13 percentage points compared to 0.53% in the previous year[5] - The company's financial expenses for Q1 2025 were CNY 34,256,843.36, down from CNY 41,420,105.76 in Q1 2024, reflecting a decrease of approximately 17.4%[25] - The company's goodwill remained stable at ¥1,982,679,226.06, unchanged from the previous period[12] - The total non-current assets slightly decreased to ¥5,094,706,515.56 from ¥5,102,522,533.62, indicating a minor decline of approximately 0.15%[12] - The company's other comprehensive income after tax for Q1 2025 was ¥61,323.97, compared to ¥1,025,645.62 in Q1 2024[18] - The company reported an investment income of CNY 81,856,466.19 for Q1 2025, significantly higher than CNY 24,883,601.31 in Q1 2024, marking an increase of approximately 228.5%[25] Accounting Standards - The company is not applying new accounting standards or interpretations starting from 2025[32]

Financial Performance - The company's operating revenue for 2024 was CNY 8,311,780,357.39, a decrease of 9.13% compared to CNY 9,147,372,720.28 in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 55,280,607.97, down 79.77% from CNY 273,296,495.22 in 2023[23]. - The basic earnings per share for 2024 was CNY 0.09, reflecting an 80.85% decrease from CNY 0.47 in 2023[24]. - The total assets at the end of 2024 were CNY 14,305,542,661.54, a slight decrease of 0.03% from CNY 14,309,993,279.77 in 2023[24]. - The net cash flow from operating activities for 2024 was CNY 646,947,379.71, down 11.34% from CNY 729,722,791.55 in 2023[23]. - The company reported a significant decline in net profit due to the impact of domestic macroeconomic conditions and price reductions in diagnostic products[24]. - The weighted average return on equity for 2024 was 1.29%, a decrease of 5.55 percentage points from 6.84% in 2023[24]. - The company's gross margin slightly decreased due to the impact of medical policy environment changes[49]. - The company achieved operating revenue of 8.312 billion RMB, a decrease of 9.13% compared to the same period last year[34]. - The net profit attributable to shareholders was 55.2806 million RMB, down 79.77% year-on-year[34]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 0.30 yuan per 10 shares to all shareholders, based on the total share capital as of the dividend distribution date[6]. - The company aims to allocate at least 20% of its distributable profits as cash dividends annually, provided the operating environment remains stable[171]. - The cash dividend amount (including tax) is CNY 18,109,208.37, which accounts for 32.76% of the net profit attributable to ordinary shareholders of the listed company in the consolidated financial statements[175]. - The cumulative cash dividend amount over the last three accounting years (including tax) is CNY 164,941,391.63, with an average annual net profit of CNY 249,419,699.54, resulting in a cash dividend ratio of 66.13%[178]. - The company has outlined a three-year dividend return plan for shareholders covering the years 2024 to 2026[145]. Corporate Governance and Management - The company has received a standard unqualified audit report from Zhonghua Certified Public Accountants[5]. - The company’s financial report has been confirmed as true, accurate, and complete by its responsible personnel[5]. - The company’s board of directors and supervisory board members have all attended the board meeting[4]. - The company held its annual general meeting on May 23, 2024, where several key resolutions were approved, including the 2023 annual financial report and the profit distribution plan for 2023[145]. - The total remuneration for directors and senior management during the reporting period amounted to 907.25 million yuan[147]. - The company has not reported any significant changes in the competitive landscape or measures taken to address potential conflicts of interest with controlling shareholders[145]. - The company has a structured compensation policy that combines fixed salaries with performance-based incentives[167]. - The company has established a performance management system that combines regular and irregular assessments to determine employee compensation and bonuses[189]. Market and Competitive Landscape - The company is a leading comprehensive service provider for medical laboratories, leveraging big data and AI to support various laboratory operations, including in vitro diagnostic products and technical services[72]. - The company faces intensified market competition in the in vitro diagnostic product sector, with increased investment from competitors leading to higher competitive risks[138]. - The domestic public hospital testing revenue reached CNY 452 billion in 2022, with a year-on-year growth of 10.4%[66]. - The IVD intermediary service market is estimated to be around CNY 1,500-1,800 billion, showing stable growth[66]. - The industry concentration has increased, with the top 10 companies' market share rising from 15% in 2021 to 28% in 2023[68]. Research and Development - The company invested 116 million RMB in R&D, maintaining high levels of investment in IVD products and digital information systems[45]. - The company has developed a series of digital information products, including the SIMS system and the Mai47 system, to support laboratory management and clinical decision-making[84]. - The company is actively integrating AI technology into its services, creating new profit points and expanding its market presence[87]. - The company has launched new products in the glycosylated hemoglobin detection market, including MQ-3000, MQ-2000T, MQ-6000, and MQ-8000, maintaining a leading position domestically[56]. - The company is focusing on AI-assisted management to reduce waste and improve efficiency in laboratory operations, such as inventory forecasting and preventive maintenance[73]. Strategic Initiatives - The company plans to focus on improving operational efficiency and exploring new market opportunities to recover from the current downturn[24]. - The company aims to enhance its service platform and expand its market presence by focusing on centralized and regional testing center businesses[132]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[148]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $100 million allocated for potential deals[149]. - The company is adopting a group management model for subsidiaries to standardize core business operations, aiming for efficient operations and improved synergy[136]. Social Responsibility and Sustainability - The company has invested CNY 220,000 in environmental protection during the reporting period[184]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[185]. - The total investment in social responsibility projects is CNY 2,351,000, including CNY 2,167,500 for scholarships and charitable funds[188]. - The company actively participates in public welfare activities, contributing to education and public health initiatives, thereby fulfilling its social responsibility[190]. - The company has maintained a record of zero accidents in production safety throughout the year, focusing on energy conservation and reducing environmental pollution as part of its sustainable development strategy[189].

上海润达医疗科技股份有限公司 2024 年度独立董事述职报告——王晶晶 本人作为上海润达医疗科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等 法律法规和《公司章程》的规定，恪尽职守、勤勉尽责，忠实履行职责，积极出 席相关会议，充分发挥作为独立董事的独立作用，维护了公司整体利益和中小股 东的合法权益。 现将 2024 年度主要工作情况报告如下： （三）行使独立董事职权的情况 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 本人是公司第五届董事会独立董事。本人基本情况如下： 中国国籍，1984 年生，会计学博士。2011 年 9 月至 2013 年 9 月任职于上海 证券交易所发展研究中心；2013 年 9 月至今任上海大学管理学院会计系讲师、 副教授；2015 年 7 月至今任上海乙木投资管理有限公司监事；2015 年 8 月至 2020 年 7 月任上海元世资产管理有限公司监事；2021 年 11 月至 2022 年 11 月任上海 大学财务处挂职副处长；2021 年 12 月至今任翌圣生物科技（上海）股份有限公 ...

上海润达医疗科技股份有限公司 （一）个人工作履历、专业背景以及兼职情况 本人是第五届董事会独立董事。本人基本情况如下： 中国国籍，1983 年生，法学博士，毕业于西南政法大学。自 2009 年开始在 浙江天册律师事务所从事律师执业，2014 年至 2019 年在浙江工业大学法学院任 教。2020 年起恢复在浙江天册律师事务所专职律师工作，主要执业领域为公司 治理、金融证券、并购、投融资和商贸等相关的诉讼及非诉讼业务，杭州市拱墅 区第一届政协委员。现担任公司独立董事。 本人作为公司的独立董事，任职符合《上市公司独立董事管理办法》第六条 规定的独立性要求，不存在影响独立性的情况。 二、独立董事年度履职情况 （一）参加董事会、股东大会情况 报告期内，本人作为公司的独立董事，参加公司董事会及股东大会会议的出 席情况如下： 2024 年度独立董事述职报告——何嘉 本人作为上海润达医疗科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等 法律法规和《公司章程》的规定，恪尽职守、勤勉尽责，忠实履行职责，积极出 席相关会议，充分发挥作为独立董事的独立 ...

上海润达医疗科技股份有限公司 2024 年度独立董事述职报告——CHAN HWANG TONG 本人作为上海润达医疗科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等 法律法规和《公司章程》的规定，恪尽职守、勤勉尽责，忠实履行职责，积极出 席相关会议，充分发挥作为独立董事的独立作用，维护了公司整体利益和中小股 东的合法权益。 现将 2024 年度主要工作情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 本人是公司第五届董事会独立董事。本人基本情况如下： 新加坡国籍，1967 年生，生物化学学士。2000 年至 2014 年历任西门子医学 诊断业务东北亚区总裁、中国区总经理、东南亚区总经理，2014 至 2018 年担任 西门子医疗大中华区总裁，自 2019 年 1 月至今担任上海惠影医疗科技有限公司 董事长、百倍医疗科技（上海）有限公司董事长、BEBIG Medical GmbH（德国 柏林）首席执行官。现担任公司独立董事。 本人作为公司的独立董事，任职符合《上市公司独立董事管理办法》第六条 规定的独立 ...

上海润达医疗科技股份有限公司 2024 年度独立董事述职报告——冯国富 本人作为上海润达医疗科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等 法律法规和《公司章程》的规定，恪尽职守、勤勉尽责，忠实履行职责，积极出 席相关会议，充分发挥作为独立董事的独立作用，维护了公司整体利益和中小股 东的合法权益。 现将 2024 年度主要工作情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 本人是公司第五届董事会独立董事。本人基本情况如下： 中国国籍，1972 年生，工商管理硕士，执业药师。曾任浙江佐力药业股份 有限公司总经理助理、投资总监、副总经理、董事会秘书；浙江佐力健康产业投 资管理有限公司副总经理；浙江凯欣医药有限公司董事等职务。2008 年 3 月至 今任浙江佐力药业股份有限公司原料药事业部总监。2015 年 11 月至今任浙江佐 力创新医疗投资管理有限公司副总经理；2017 年 1 月至今任浙江佐力药业股份 有限公司董事；2019 年 11 月至今任浙江佐力百草中药饮片有限公司董事；2021 年 1 月 ...

二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0900 | 0.4700 | -80.85 | 0.7200 | | 每股净资产（元） | 7.14 | 7.06 | 1.13 | 6.52 | | 每股公积金(元) | 2.06 | 1.94 | 6.19 | 1.59 | | 每股未分配利润(元) | 3.87 | 3.92 | -1.28 | 3.74 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 83.12 | 91.47 | -9.13 | 104.94 | | 净利润(亿元) | 0.55 | 2.73 | -79.85 | 4.18 | | 净资产收益率(%) | 1.29 | 6.84 | -81.14 | 11.37 | 数据四舍五入，查看更多财务数据>> 前十大流通股东累计持有： 23766.85万股，累计占流通股比： 39.3 ...

润达医疗（603108）公告，2025年第一季度营业收入16.62亿元，同比下降19.81%。净亏损6925.87万 元，去年同期净利润2260.38万元。 ...

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 刘辉先生持有公司股份31,528,771股，占公司总股本的5.22%。本次部分解质押及质押延期后，其累计 质押的股份数为9,630,000股，占其所持股份的30.54%，占公司总股本的1.60%。 ● 刘辉先生及朱文怡女士为一致行动人，截至本公告日，两人合计持有公司股份63,047,179股，占公司 总股本的10.44%。合计质押的股份数为20,170,000股，占其所持股份的31.99%，占公司总股本的 3.34%；合计冻结的股份数为2,904,000股，占其所持股份的4.61%。 上海润达医疗科技股份有限公司（以下简称"公司"）接到股东刘辉先生通知，获悉其在2025年4月22 日，将原质押给中信建投证券股份有限公司（以下简称"中信建投"）的11,630,000股公司股份办理了部 分解除质押及质押延期购回的手续，本次解质押股份为2,000,000股，延期购回股份为9,630,000股。原质 押情况详见公司临时 ...